An observational study in Melanoma, NSCLC and Positron-Emission Tomography, sponsored by University Hospital, Brest. Completed at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-06.
Sponsored by University Hospital, Brest · Observational
Study the EFS and OS according to 18FDG PET in patients with melanoma or non small cell lung cancer treated by immunotherapy.
Study EFS in patients with melanoma or NSCLC treated by immunotherapy (anti CTLA4 or anti PDL1) and performed18FDG PET
Multicentric retrospective study
3,006 studies on the registry are indexed under Melanoma; 520 are open to participants now.
This study's enrollment of 70 is below the median of 182 across 438 observational studies indexed under Melanoma.
Browse Melanoma studies →University Hospital, Brest is the lead sponsor of 594 studies on the registry; 135 are open to participants now.
Counted across the registry records on this site, refreshed daily.
70 patients (50 patients with melanoma and 20 patients with NSCLC)
Exclusion Criteria:
measure of progression free survival (obtained by the delay between the date of initiation of immunotherapy until the date of first documented progression disease in patients with melanoma or NSCLC treated by immunotherapy
From date of initiation of treatment until the date of first documented progression disease according to different criteria in interim PET/CT 1. 18F-FDG PET/CT imaging was performed prior to (18F-FDG PET/CT 0) and 14 weeks after ICI onset (18F-FDG PET/CT 1). Assessment of patient response to treatment was done according to RECIST1.1, iRECIST, PERCIST and PECRIT criteria.
Time frame: up to 50 months
measure of overall survival (obtained by the delay between the date of initiation of immunotherapy until the date of death related to disease in patients with melanoma or NSCLC treated by immunotherapy
From date of initiation of treatment until the date of death related to disease according to different criteria in interim PET/CT 1. 18F-FDG PET/CT imaging was performed prior to (18F-FDG PET/CT 0) and 14 weeks after ICI onset (18F-FDG PET/CT 1). Assessment of patient response to treatment was done according to RECIST1.1, iRECIST, PERCIST and PECRIT criteria.
Time frame: up to 50 months
Study different criteria (RECIST, iRECIST, PERCIST and PECRIT) to predict PFS or OS
Interpretation according to 4 criteria to predict response to immunotherapy
Time frame: up to 50 months
study the potential correlation between PET data and clinicobiological data
correlation between adverse events (AE) due to immunotherapy described on PET data and AE detected on clinicobiological data
Time frame: up to 50 months
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Brest